LAS VEGAS — Enhanced Group posted a net loss of $61.9 million on revenue of $17.7 million following its debut event. The financial results were reported after the company's debut event in May.

The organization attributed the loss to the inaugural Enhanced Games, costs associated with its special purpose acquisition company merger, and a clinical trial for one of its supplements. The inaugural Enhanced Games took place in Las Vegas and allowed competitors to take performance-enhancing supplements.

"The results reflect an intentional decision to invest heavily in its inaugural Enhanced Games, as the foundational platform for both its sports business and as a customer acquisition engine for its performance medicine platform," Group said. Max Martin, Enhanced Group cofounder and CEO, said groundwork is being laid for the second annual Enhanced Games next year. Martin stated that Enhanced Group will become a "globally recognized sports brand" that is the "only organization to have successfully conducted a medically supervised enhanced sporting event in history." Official details for the second annual Enhanced Games have not been announced.

Critics challenged the model's safety and intent. The World Anti-Doping Agency called the Enhanced Games "dangerous and irresponsible." The U.S. Anti-Doping Agency stated the Enhanced Games were "being done purely for the entertainment and shock value, with no bearing on the long-term health of the athlete."

What's New

The Enhanced Games' medical board initiated a clinical trial lasting more than two months to study the effects of the substances used by athletes. Enhanced Group Inc. filed form S-1 on 2026-05-11.

Research titled IMF Executive Board Approves US$38.2 Million PRGF Arrangement for Chad and Grants Additional Interim Assistance of US$2.1 Million Under the Enhanced HIPC Initiative was also noted in recent filings.

Why It Matters

The financial disclosure shows the capital intensity of launching a sports league that permits performance-enhancing substances under medical supervision. Enhanced Group is backed by billionaire investor Peter Thiel and Donald Trump Jr.'s investment firm, indicating private capital support despite the initial deficit.

The divergence between the company's characterization of the event as a foundation for performance medicine and the condemnation from anti-doping agencies reflects the regulatory and ethical debates surrounding the venture. The lack of announced details for the second annual event leaves the timeline for future competitions uncertain.